EICHORCondition: Solid Tumor · Sponsor: IDEAYA Biosciences
This is a Phase 1, open-label, multicenter, dose escalation and expansion study of the safety, PK, PD, and preliminary anti-tumor activity of IDE397 as a single agent and in combination with sacituzumab govitecan (SG), in adult patients with selected advanced or metastatic MTAP-deleted advanced solid tumors who are unresponsive to standard of care therapy. IDE397 is a small molecule inhibitor of methionine adenosyltransferase 2 alpha (MAT2A).
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Honor Health Research Institute | Scottsdale, Arizona, United States | — |
| Rockefeller Cancer Institute | Little Rock, Arkansas, United States | — |
| City of Hope | Duarte, California, United States | — |
| Orlando Health Cancer Institute | Orlando, Florida, United States | — |
| Indiana University Health Hospital | Indianapolis, Indiana, United States | — |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore, Maryland, United States | — |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | — |
| Columbia University Medical Center - Herbert Irving Pavilion | New York, New York, United States | — |
| Weill Cornell Medical College | New York, New York, United States | — |
| Stephenson Cancer Center | Oklahoma City, Oklahoma, United States | — |
| LifeSpan - Brown University | Providence, Rhode Island, United States | — |
| Sarah Cannon Research Institute | Nashville, Tennessee, United States | — |
+ 25 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04794699